Cell therapy and gene therapy are related fields that often overlap. Cell therapy works by restoring or modifying cells, or using them to deliver treatments, and these cells are prepared outside the body before being given to the patient. They can be derived from the patient (autologous) or a donor (allogeneic). Gene therapy, on the other hand, treats disease by replacing, turning off, or adding genes to cells, either directly in the body (in vivo) or outside the body (ex vivo). Both types of therapy rely on the cells maintaining their integrity, viability, and function throughout manufacturing and delivery.
Driven by advances in science and growing clinical demand, the global cell and gene therapy market, valued at $27.02 billion in 2025, is projected to reach approximately $232.22 billion by 2035, growing at a 24% compound annual growth rate, according to a study by Towards Healthcare, a sister firm of Precedence Research.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.